Cambridge spinout Crescendo Biologics has secured $70m in an IP Group and EMBL Ventures-backed round.
Crescendo Biologics, a UK-based immunotherapy developer spun out from University of Cambridge, closed a $70m series B round today that featured commercialisation firm IP Group.
EMBL Ventures, the investment arm of European Molecular Biology Laboratory, also contributed to the round, which was led by Andera Partners, the investment firm previously known as Edmond de Rothschild Investment Partners, through its Biosdiscovery V fund
Takeda Ventures, the corporate venturing subsidiary of pharmaceutical firm Takeda, Sofinnova Partners and Quan Capital, through its Quan…